Clinical trials: Circulating Tumor Cell
Prostate Cancer, Prostate Adenocarcinoma
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
This study will follow men with metastatic castration resistant prostate cancer throughout their standard of care treatment for their disease to determine if the presence of different genes or proteins can predict which patients…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
- Trial name
- ARCTIC (NCT06141993)
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Duke University
Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment
Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer
This pilot study aims to trial multimodal early response assessment to enable therapy adaptions in the context of non-operative therapy strategies of locally advanced rectal cancer (LARC) for development of a non-invasive…
- Conditions
- Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment, Radiotherapy, Adaptive Treatment
- Trial name
- PRIMO (NCT05524012)
- Testing
- Blood sample, MRI scan
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Jena University Hospital
Renal Cell Carcinoma, Circulating Tumor Cell
Circulating Tumor Cell Reducing No-touch Nephrectomy
This study will study circulating tumor cell (CTC) release during laparoscopic radical nephrectomy (LRN) for RCC. The main objective is to determine if CTC release can be reduced during RN by using a no-touch technique, with an…
- Trial name
- CITO-CERENE (NCT05070637)
- Testing
- No-touch laparoscopic radical nephrectomy, Conventional laparoscopic radical nephrectomy, Laparoscopic total nephrectomy control arm
- Where
- Portugal
- Volunteers
- 44 people
- Sponsor
- Hospital de Santa Maria, Portugal
Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma
Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer
This prospective observational study evaluates a blood-based circulating tumor DNA (ctDNA) test in patients with muscle-invasive bladder cancer or upper tract urothelial cancer.
- Conditions
- Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma, Urothelial Carcinoma (UC)
- Trial name
- BLUT-DNA (NCT07756437)
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- AZ Sint-Lucas Gent
Metastatic Breast Cancer, HER2 Negative Primary Tumor
Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Patients with metastatic breast cancer considered HER2 negative are screened for HER2-amplified circulating tumor cells. If at least HER2-amplified circulating tumor cell is detected, patients are treated by Trastuzumab …
- Trial name
- NCT01975142
- Testing
- Trastuzumab - Emtansine
- Where
- 10 sites in France
- Volunteers
- 155 people
- Sponsor
- Institut Curie
Stomach Neoplasms, Metastasis
Detection of CTC and ctDNA in the Diagnosis of Metastasis in Gastric Cancer
To investigate the value of CTCs and ctDNA in the diagnosis of metastasis in ascites/peritoneal flushing fluid and blood; To investigate the influence of laparoscopic CO2 pneumoperitoneum establishment on peritoneal and…
- Trial name
- CTC_ctDNA (NCT05208372)
- Testing
- CTC test, ctDNA test
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- First Hospital of China Medical University
Melanoma
Serial Tumour Biopsies and Blood Biomarkers in Melanoma
Recent advances in understanding how cancer develops and spreads have led to effective new treatments and improved outcomes for patients with melanoma.
- Trial name
- NCT04493723
- Testing
- Surgery, Venepuncture
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- The Christie NHS Foundation Trust
Squamous Cell Carcinoma of the Oropharynx
HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma
The study will evaluate the safety and effectiveness of a lower than standard dose of radiation for definitive or adjuvant treatment of head and neck squamous cell carcinomas.
- Trial name
- HN001 (NCT05962242)
- Testing
- Radiation Therapy
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Virginia
Prostate Cancer, Immune Profile
Immune Profiles and Circulating Tumor Cell Status Following Prostate Cryotherapy
The change of immune profiles and existence of circulating tumor cells following prostate cryotherapy may be correlated with the clinical outcome.
- Conditions
- Prostate Cancer, Immune Profile, Circulating Cancer Cells, Clinical Corelation
- Trial name
- NCT01454037
- Testing
- Prostate cryotherapy, Radical prostatectomy, Radiation
- Where
- Taiwan
- Volunteers
- 160 people
- Sponsor
- National Taiwan University Hospital
Colorectal Cancer
A Study of Circulating Immune Cell Activity Changes in Blood of Colorectal Cancer Patients
Previous studies have shown that colorectal cancer patients' prognosis and overall survival was related with immune cell expression in patients' tissue.
- Trial name
- NCT02869269
- Testing
- Early stage, Late stage
- Where
- South Korea
- Volunteers
- 67 people
- Sponsor
- Konkuk University Medical Center
Circulating Tumor Cell, Nasopharyngeal Carcinoma
Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC
The prospective observational clinical study will recruit 50 metastatic nasopharyngeal carcinoma (mNPC) patients, detecting patient's chemosensitivity with the circulating tumor cells (CTCs) from peripheral blood and prdicting…
- Conditions
- Circulating Tumor Cell, Nasopharyngeal Carcinoma, Distant Metastases.Clinical, Effects of Chemotherapy
- Trial name
- NCT04544969
- Testing
- cisplatin-based chemotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Early Detection of Cancer, Cancer
PATHFINDER 2: A Multi-Cancer Early Detection Study
This is a prospective, multi-center interventional study of the GRAIL multi-cancer early detection (MCED) test with return of test results for participants enrolled through healthcare systems in North America.
- Trial name
- NCT05155605
- Testing
- Multi-Cancer Early Detection Test
- Where
- 56 sites in United States, Canada
- Volunteers
- 35,883 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Oropharynx Squamous Cell Carcinoma, Oropharynx Cancer
Circulating Biomarkers in Oropharyngeal Cancers
The goal of this observational longitudinal study is to learn about circulating tumor Human Papilloma Virus-DNA (ctHPV-DNA) as a biomarker for HPV positive oropharyngeal cancer and cancer of unknown primary of the head and neck.
- Conditions
- Oropharynx Squamous Cell Carcinoma, Oropharynx Cancer, Tonsillar Cancer, Base of the Tongue Carcinoma
- Trial name
- CIRCOS (NCT05904327)
- Where
- Sweden
- Volunteers
- 130 people
- Sponsor
- Region Örebro County
Prostate Cancer, Prostate Adenocarcinoma
Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC
Prostate cancer is a leading cause of mortality and morbidity. The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC, T-cells and circulated tumor DNA in prostate cancer…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic
- Trial name
- NCT03494803
- Where
- Kazakhstan
- Sponsor
- HKGepitherapeutics
Head and Neck Cancer, Advanced Cancer
Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)
This study aims to study the kinetics of ctDNA levels after the first dose of immune checkpoint inhibitor in patients with recurrent or metastatic head and neck cancer.
- Conditions
- Head and Neck Cancer, Advanced Cancer, Metastatic Cancer, HNSCC
- Trial name
- NCT04606940
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- University Health Network, Toronto
Non-Small Cell Lung Cancer, Adjuvant Therapy
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
This multicenter, randomized, open-label, phase II trial is designed to evaluate the efficacy and safety of adjuvant sintilimab in patients with completely resected non-small cell lung cancer who remain at high risk of recurrence…
- Conditions
- Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- RICA (NCT07748325)
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sichuan University
Locally Advanced Breast Cancer, Metastatic (Stage IV) Breast Cancer
Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer
The purpose of this study is to identify tumor cells in the bloodstream (Circulating Tumor Cells, CTC's) from patient's with locally advanced or metastatic (stage IV) breast cancer.
- Conditions
- Locally Advanced Breast Cancer, Metastatic (Stage IV) Breast Cancer, Stage III-IV Breast Cancer or Inflammatory
- Trial name
- NCT01048918
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- City of Hope Medical Center
Hepatocellular Carcinoma, Circulating Tumor Cell
Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
On the basis of previous retrospective studies, the Task Force will further optimize the CTCs longitudinal surveillance model and initially validate the subclonal origin (CTC-DNA) of recurrent/metastatic foci derived from CTCs at…
- Conditions
- Hepatocellular Carcinoma, Circulating Tumor Cell, Recurrence, Surgery
- Trial name
- NCT06317896
- Testing
- circulating tumor cells
- Where
- 3 sites in China
- Volunteers
- 82 people
- Sponsor
- Zhujiang Hospital
Non Small Cell Lung Cancer
A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells
Early non-small cell lung cancer (NSCLC), treated by surgery or radiotherapy in the case of inoperability, relapses in almost 50% of cases.
- Trial name
- LUNGadenosine (NCT05648188)
- Testing
- Sample
- Where
- France
- Sponsor
- Centre Hospitalier Universitaire de Nice